Logan Lutton is the Associate Editor of Managed Healthcare Executive. She covers healthcare policy and the latest developments in schizophrenia, HIV and ADHD, with a focus on the advocates and researchers working in these areas.
Prior to joining MHE, Logan was a member of the editorial team at Medical Economics, which is also part of MJH Life Sciences. During her tenure, the publication marked its 100th anniversary, and she contributed to its centennial issue, which received a Jesse H. Neal Award. Her contribution, "The doctor is in...your TV," is a feature on the history of physicians in popular culture.
Logan earned her bachelor’s degree in Journalism and Mass Communication at Kent State in 2019.
Conversations around menopause symptoms are becoming more common, but there is such a thing as potentially calling too much attention, especially in the workplace, according to Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health.
Gaps in funding caused by the potential $5 billion budget cut to the National Institutes of Health would be “almost impossible” to fill, according to Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D.
Bias and stigma are to blame for the way women’s health research has fallen behind, according to Monica Christmas, M.D., director of UChicago Medicine’s menopause program and the Center for Women's Integrated Health and Valentina Sartori, Ph.D., a partner in McKinsey & Company’s Life Sciences Practice, and affiliated leader of the McKinsey Health Institute.
Funding will be cut to $10 million, which is a nearly 90% decrease from 2024’s budget of $98 million.
Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D, spoke with Managed Healthcare Executive, about the possible impacts of the NIH’s cuts to indirect research funding.
Here’s what you missed this week on Managed Healthcare Executive.
Gomekli is the second ever FDA-approved treatment for rare tumor disease, NF1-PN and the first to be approved for both adult and pediatric patients.
The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic atrophy secondary to age-related macular degeneration.
The group released a statement today expressing that they are eager to work with Robert F. Kennedy Jr. to eradicate HIV when steps into his role as the Secretary of Health and Human Services.
Positive HIV status as well as socioeconomic disadvantages, not breastfeeding, are associated with infant length and birth weight, according to the results of a new South African study.
Menopausal patients are most interested in learning more about non-hormonal treatments to address their symptoms, according to the results of an international survey led by the Menopause Priority Setting Partnership (MAPS). Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health, discussed the survey details with Managed Healthcare Executive.
Judi Health manages medical and pharmacy claims on the same platform to cut administrative cost.
Here’s what you missed this week on Managed Healthcare Executive.
The GLP-1 compound drug sold by Hims and Hers is not approved by the FDA and its Super Bowl ad fails to list any risks associated with taking the medication.
PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still uncertainty and interruptions, partly because many PEPFAR programs are implemented through USAID, which has been largely shutdown by the news administration.
Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, talks with Managed Healthcare Executive about Robert F. Kennedy Jr., President Donald Trump’s HHS secretary nominee.
Laurie Ratliff was diagnosed with metastatic breast cancer 25 years ago, and she’s continuing to beat the odds while advocating for aesthetic flat closure as a viable breast reconstruction option.
An overview of menopause taboo, the lingering effects of the Women’s Health Initiative study and what employers can do support their menopausal workers, according to Stephanie Faubion, M.D., director of the Mayo Clinic’s Center for Women’s Health and medical director of The Menopause Society.
Potential threats to HIV care and fallout over the next four years, according to Jose Abrigo, Esq., HIV project director at Lambda Legal Defense and Education Fund and Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.
Here’s what you missed this week on Managed Healthcare Executive.
A new bipartisan bill aims to cancel the 2.83% cut to Medicare payments to physician practices.
In 2021 book attacking Anthony Fauci, M.D., Robert F. Kennedy Jr. casts doubt on HIV being the sole cause of AIDS and presents arguments made by "HIV deniers" that believe it is bystander in the immunosuppression that characterizes AIDS.
A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research shows.
Here’s what you missed this week on Managed Healthcare Executive.
Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Ways workplaces and insurance companies have begun to support menopausal women, according to Jenifer Allbright, Director of G&A Beneficial at G&A Partners.
The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22, 2025.
The development of avian influenza vaccines is the main priority amid rising cases in the United States.
Datroway reduced disease progression by 37% when compared with chemotherapy.
